This website has been developed by Besins Healthcare (UK) Ltd.

This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) within the UK.

Please confirm that:

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Why Testogel®?


Testogel® is indicated in adults as testosterone therapy (TTh) for male hypogonadism when testosterone deficiency (TD) has been confirmed by clinical features and biochemical tests.1,2

The recommended daily dose is two pump actuations, or one sachet. The pump enables the prescriber to easily adjust the dose if required.*1

Normal testosterone levels** were achieved at day 182 in 82.2% (139/169) of testosterone deficient men treated with an optimised dose vs. 28.6% of men receiving placebo in a randomised placebo-controlled trial involving 274 patients.1,3

Well tolerated: 1–10% incidence of skin reactions.1,2

Please refer to the safety information for further details regarding undesirable side effects.

Testogel® 40.5 mg, transdermal gel in sachet contains the same effective 16.2 mg/g gel found in the Testogel® pump, making both products interchangeable.

This gives patients the flexibility to easily switch between either product.

Comprehensive online support for patients that aims to instil confident, regular use of treatment. The Patient Support Programme includes our patient website, T Track app, informative videos and a patient leaflet.

*Testosterone levels should be monitored at baseline and at regular intervals during treatment. Clinicians should adjust the dosage depending on the clinical or laboratory response in individual patients. **In this study, a normal range was defined as a serum total testosterone average concentration of 300–1000ng/dL (10.4–34.7 nmol/L).2

Want to talk Testogel®?

    *Required field

    Besins Healthcare (UK) Ltd would like to request your consent for the company to use your email address to send information to you on the subject areas listed below. Please indicate your consent preference below.

    I agree to receiving information by email on the following topics:

    For example, an appointment request from a key account manager, information about the safety and effectiveness of our medicines, educational support for healthcare professionals and patients associated with our products.

    For example, educational events on the management of conditions associated with our medicine.

    By clicking any of the above, you agree to Besins Healthcare terms of use and privacy policy.

    If you wish to amend or remove the consent you have selected above in the future, please email


    1. Testogel® 16.2 mg/g gel – Summary of Product Characteristics (SmPC) – Accessed April 2021.
    2. Testogel® 40.5 mg, transdermal gel in sachet – Summary of Product Characteristics (SmPC) – Accessed February 2022.
    3. Kaufman JM, Miller MG, Garwin JL, et al. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med. 2011;8(7):2079–2089.

    TES/2022/046. February 2023.

    Adverse event reporting

    Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: